ChromaDex Corporation (NASDAQ:CDXC) saw some unusual options trading on Monday. Stock investors acquired 607 call options on the company. This represents an increase of approximately Infinity compared to the typical volume of 0 call options.

CDXC has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating on shares of ChromaDex Corporation in a research note on Monday, September 11th. Ladenburg Thalmann Financial Services initiated coverage on ChromaDex Corporation in a research note on Monday, September 25th. They issued a “buy” rating and a $7.00 price objective for the company. ValuEngine upgraded ChromaDex Corporation from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Finally, Zacks Investment Research cut ChromaDex Corporation from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. ChromaDex Corporation presently has a consensus rating of “Hold” and an average price target of $6.33.

Shares of ChromaDex Corporation (NASDAQ:CDXC) opened at $5.96 on Thursday. ChromaDex Corporation has a 52 week low of $2.25 and a 52 week high of $6.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.12 and a current ratio of 5.03.

In other news, major shareholder Step Holdings Ltd Pioneer acquired 786,167 shares of ChromaDex Corporation stock in a transaction on Friday, August 18th. The stock was bought at an average price of $2.60 per share, for a total transaction of $2,044,034.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.59% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in CDXC. Goldman Sachs Group Inc. raised its stake in shares of ChromaDex Corporation by 870.6% during the second quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after purchasing an additional 163,817 shares during the last quarter. North Star Investment Management Corp. raised its stake in shares of ChromaDex Corporation by 78.9% during the second quarter. North Star Investment Management Corp. now owns 265,334 shares of the company’s stock worth $1,014,000 after purchasing an additional 117,000 shares during the last quarter. LMR Partners LLP purchased a new stake in shares of ChromaDex Corporation during the second quarter worth approximately $347,000. Bank of Montreal Can purchased a new stake in shares of ChromaDex Corporation during the second quarter worth approximately $168,000. Finally, Thompson Davis & CO. Inc. purchased a new stake in shares of ChromaDex Corporation during the third quarter worth approximately $128,000. Institutional investors and hedge funds own 8.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/11/16/chromadex-corporation-sees-unusually-large-options-volume-cdxc.html.

About ChromaDex Corporation

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Receive News & Ratings for ChromaDex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.